Evidence map›Paper›PMID 39040988›Full record

ArticleJournal of bone and joint infection2024

Fred Ruythooren, Stijn Ghijselings, Melissa Depypere, Willem-Jan Metsemakers, Liesbet Henckaerts, Nathalie Noppe, Georges Vles

Abstract readCase Reports
In one paragraph

Article in Journal of bone and joint infection, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fred RuythoorenDepartment of Orthopaedic Surgery, University Hospitals Leuven - Gasthuisberg, Leuven, Belgium.
Stijn GhijselingsDepartment of Orthopaedic Surgery, University Hospitals Leuven - Gasthuisberg, Leuven, Belgium.
Melissa DepypereDepartment of Laboratory Medicine, University Hospitals Leuven - Gasthuisberg, Leuven, Belgium.
Willem-Jan MetsemakersDepartment of Trauma Surgery, University Hospitals Leuven - Gasthuisberg, Leuven, Belgium.
Liesbet HenckaertsDepartment of Microbiology, Immunology and Transplantation, Laboratory for Clinical Infectious and Inflammatory Disorders, KU Leuven, Leuven, Belgium.
Nathalie NoppeDepartment of Radiology, University Hospitals Leuven - Gasthuisberg, Leuven, Belgium.
Georges VlesDepartment of Orthopaedic Surgery, University Hospitals Leuven - Gasthuisberg, Leuven, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ocrelizumab - a monoclonal anti-CD20 antibody used in treatment of multiple sclerosis (MS) - marks significant progress in treating autoimmune diseases but raises susceptibility to opportunistic infections due to hypogammaglobulinemia. A young MS patient developed osteomyelitis from persistent

Identifiers

PMID39040988
PMCPMC11262025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.